Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for Q3UFT3

Entry ID Method Resolution Chain Position Source
AF-Q3UFT3-F1 Predicted AlphaFoldDB

60 variants for Q3UFT3

Variant ID(s) Position Change Description Diseaes Association Provenance
rs3408131549 12 K>E No EVA
rs3408477203 12 K>M No EVA
rs3408477195 29 T>I No EVA
rs3408311844 30 Y>* No EVA
rs3406439647 31 R>* No EVA
rs3389483686 63 T>S No EVA
rs3389456922 74 Y>F No EVA
rs3389436959 152 D>E No EVA
rs3389498164 186 S>F No EVA
rs3389469647 192 K>* No EVA
rs254747371 216 K>R No EVA
rs3408130489 224 P>S No EVA
rs47927011 225 L>M No EVA
rs3408353089 226 E>G No EVA
rs3389498198 232 G>W No EVA
rs3389401145 245 L>F No EVA
rs3389498118 260 Y>C No EVA
rs3389489289 271 Y>C No EVA
rs3389469669 290 N>K No EVA
rs3406437220 316 D>G No EVA
rs3389483099 316 D>N No EVA
rs3408242858 317 M>L No EVA
rs3408664251 318 W>G No EVA
rs3408130503 319 P>T No EVA
rs3389490910 330 C>G No EVA
rs3389436968 359 K>R No EVA
rs1135341283 361 R>C No EVA
rs1135341283 361 R>S No EVA
rs3389498186 362 C>S No EVA
rs3389483644 367 H>L No EVA
rs3389436995 382 S>T No EVA
rs1132661584 385 R>L No EVA
rs3389505937 402 N>I No EVA
rs1133982948 404 H>Q No EVA
rs3389490866 407 R>G No EVA
rs3389493753 423 Y>H No EVA
rs3389500989 440 E>K No EVA
rs3408382021 457 W>R No EVA
rs264498598 465 R>H No EVA
rs3389500910 476 S>C No EVA
rs3389483079 480 T>S No EVA
rs3389493760 496 T>A No EVA
rs228443942 510 A>T No EVA
rs3389456931 517 P>S No EVA
rs1133792286 528 R>Q No EVA
rs3389500971 562 R>G No EVA
rs3408353116 581 Q>L No EVA
rs3389483035 594 C>R No EVA
rs3389490412 598 T>I No EVA
rs1132523440 664 C>S No EVA
rs3389505953 678 S>N No EVA
rs3389446992 706 S>F No EVA
rs240148961 713 A>T No EVA
rs3389483040 746 L>Q No EVA
rs3408353125 787 L>P No EVA
rs50106372 829 V>F No EVA
rs50106372 829 V>I No EVA
rs3389490871 870 N>Y No EVA
rs864279974 875 K>E No EVA
rs864284247 875 K>R No EVA

No associated diseases with Q3UFT3

1 regional properties for Q3UFT3

Type Name Position InterPro Accession
domain CABIT domain 32 - 312 IPR025946

Functions

Description
EC Number
Subcellular Localization
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

No GO annotations of cellular component

Name Definition
No GO annotations for cellular component

1 GO annotations of molecular function

Name Definition
proline-rich region binding Binding to a proline-rich region, i.e. a region that contains a high proportion of proline residues, in a protein.

5 GO annotations of biological process

Name Definition
cellular response to epidermal growth factor stimulus Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an epidermal growth factor stimulus.
epidermal growth factor receptor signaling pathway The series of molecular signals initiated by binding of a ligand to the tyrosine kinase receptor EGFR (ERBB1) on the surface of a cell. The pathway ends with regulation of a downstream cellular process, e.g. transcription.
positive regulation of cell division Any process that activates or increases the frequency, rate or extent of cell division.
positive regulation of cell population proliferation Any process that activates or increases the rate or extent of cell proliferation.
positive regulation of ERK1 and ERK2 cascade Any process that activates or increases the frequency, rate or extent of signal transduction mediated by the ERK1 and ERK2 cascade.

2 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
Q75VX8 GAREM2 GRB2-associated and regulator of MAPK protein 2 Homo sapiens (Human) PR
Q9H706 GAREM1 GRB2-associated and regulator of MAPK protein 1 Homo sapiens (Human) PR
10 20 30 40 50 60
MDPAPSLGCS LKDVKWSPVA MPLDLLVSTY RLPQIARLDS GECVEGLREN DFLLIHSCRQ
70 80 90 100 110 120
WTTITAHSLE EGHYVIGPKI EIPVHYAGQF KLLEQDRDIK EPVQYFNSVE EVAKAFPERV
130 140 150 160 170 180
YVMEEITFNV KVASGECNED TEVYNITLCT GDELTLMGQA EILYAKTFKE KSRLNTIFKK
190 200 210 220 230 240
IGKLNSISKL GKGKMPCLIC MNHRTNESIS LPFQCKGRFS TRSPLELQMQ EGEHTIRNIV
250 260 270 280 290 300
EKTRLPVNVT VPSPPPRNPY DLHFIREGHR YKFVNIQTKT VVVCCVLRNN KILPMHFPLH
310 320 330 340 350 360
LTVPKFSLPE HQVKGDMWPE TLVHHWLGIC QEQFDIDEYS RAVRDVKTDW NEDCKSPKKG
370 380 390 400 410 420
RCSGHNHLPN SLSYARDELT QSFHRLSVCV YGNNLHGNSE VNLHGCRDLG GEWAPFPHDI
430 440 450 460 470 480
LPYQDSGDSG SDYLFPEANE ESAGIPGKTE VPYEELWLEE GKPSRQPLTR SLSEKSRCDT
490 500 510 520 530 540
LRGSTRSTCA PSSPPTPATL GATIKSSEIA LPPPPVPPKS EAVREECRLL NAPPVPPRSA
550 560 570 580 590 600
KPLSTSPSIP PRTVKPVRPQ TRSPSPTLSY YSSGLHNIIT QSDTSPPNSA PVSCYPCTRV
610 620 630 640 650 660
KSDSVDPKSP FGSPSAEALS SRLSWPNHYS GASENQTRSD FLLDPSRSYS YPRQKTPGTP
670 680 690 700 710 720
KRTCPAPFDF EGCELLGSPP STTSAEFSSS GVPSCPKSAS YCLENSEDNS FAAGMTKQSV
730 740 750 760 770 780
SCPALPPRAP KPVEQKATPE TSPLPLKIDG AEEDPTAGSL DLSEDQYFVR KGMQDIFSVS
790 800 810 820 830 840
YPFSSPLHLQ LAPRSCGDGS PWQPPADLSG LSIEEVSKSL RFIGLSEDVI AFFVTEKIDG
850 860 870
NLLVQLTEEI LSEDFKLSKL QVKKILQFIN GWRPKI